Relay Therapeutics Dividendos y recompras

Dividendo controles de criterios 0/6

Relay Therapeutics no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-36.6%

Rendimiento de la recompra

Rendimiento total para el accionista	-36.6%
Rendimiento futuro de los dividendos	0%
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de RLAY han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de RLAY han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Relay Therapeutics vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de RLAY con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (RLAY)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Biotechs)	2.3%
Analista de previsiones (RLAY) (hasta 3 años)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de RLAY en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de RLAY en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de RLAY para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que RLAY no ha comunicado ningún pago.

Relay Therapeutics Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Relay Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Relay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000003 million.

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Relay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000003 million.

Relay Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Relay Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with Rly-2608

Consensus revenue estimates increase by 2,448%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

Relay Therapeutics, Inc., Annual General Meeting, Jun 03, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates decrease by 12%

Relay Therapeutics: Platform More Important Than Programs

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 10%

Relay Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

New major risk - Revenue and earnings growth

Relay Therapeutics, Inc. announced that it has received $30 million in funding

Relay Therapeutics, Inc. announced that it expects to receive $30 million in funding

Price target decreased by 7.1% to US$22.87

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 1,470%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Consensus revenue estimates decrease by 10%

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Relay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 8.4% to US$27.21

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.3% to US$29.04

Price target decreased by 12% to US$31.33

Consensus revenue estimates increase by 39%

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

CEO, President & Director exercised options and sold US$670k worth of stock

Chief Legal Officer & Secretary notifies of intention to sell stock

High number of new directors

CEO, President & Director exercised options and sold US$660k worth of stock

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings released: US$0.76 loss per share (vs US$0.66 loss in 3Q 2021)

President of Research & Development exercised options and sold US$149k worth of stock

Relay Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

CEO, President & Director exercised options and sold US$711k worth of stock

President of Research & Development exercised options and sold US$146k worth of stock

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Relay Therapeutics, Inc. Presents Data at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Relay Therapeutics, Inc. Presents Data at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Consensus revenue estimates fall by 20%

Why did Relay Therapeutics stock drop today?

President of Research & Development exercised options and sold US$153k worth of stock

President of Research & Development exercised options and sold US$313k worth of stock

Consensus forecasts updated

President of Research & Development exercised options and sold US$127k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Relay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Relay Therapeutics, Inc. Announces Appointment of Sekar Kathiresan to the Board

President of Research & Development exercised options and sold US$127k worth of stock

President of Research & Development notifies of intention to sell stock

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise

Price target decreased to US$40.00

Price target decreased to US$43.86

President of Research & Development exercised options and sold US$267k worth of stock

High number of new and inexperienced directors